vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and MICROVISION, INC. (MVIS). Click either name above to swap in a different company.
MICROVISION, INC. is the larger business by last-quarter revenue ($223.0K vs $169.0K, roughly 1.3× Aligos Therapeutics, Inc.). On growth, Aligos Therapeutics, Inc. posted the faster year-over-year revenue change (-72.1% vs -86.5%). Over the past eight quarters, Aligos Therapeutics, Inc.'s revenue compounded faster (-50.7% CAGR vs -51.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
MicroVision Inc. is a technology company specializing in advanced LiDAR sensors, miniature display solutions, and perception software. Its core products serve automotive ADAS, augmented reality devices, consumer electronics, and industrial automation markets, delivering high-precision, low-power sensing technologies for next-generation smart applications.
ALGS vs MVIS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $223.0K |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | -72.1% | -86.5% |
| Net Profit YoY | 75.8% | -21.2% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $169.0K | $223.0K | ||
| Q3 25 | $741.0K | $241.0K | ||
| Q2 25 | $965.0K | $155.0K | ||
| Q1 25 | $311.0K | $589.0K | ||
| Q4 24 | $606.0K | $1.6M | ||
| Q3 24 | $1.3M | $190.0K | ||
| Q2 24 | $1.1M | $1.9M | ||
| Q1 24 | $694.0K | $956.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-31.5M | $-14.2M | ||
| Q2 25 | $-15.9M | $-14.2M | ||
| Q1 25 | $43.1M | $-28.8M | ||
| Q4 24 | $-82.2M | $-31.2M | ||
| Q3 24 | $-19.3M | $-15.5M | ||
| Q2 24 | $5.1M | $-23.9M | ||
| Q1 24 | $-34.9M | $-26.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 6.6% | ||
| Q4 24 | — | -149.5% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 18.2% | ||
| Q1 24 | — | -33.6% |
| Q4 25 | — | — | ||
| Q3 25 | -3827.4% | -5278.4% | ||
| Q2 25 | -1924.0% | -9455.5% | ||
| Q1 25 | -6187.5% | -2383.7% | ||
| Q4 24 | -3393.2% | -1119.5% | ||
| Q3 24 | -1610.5% | -8266.3% | ||
| Q2 24 | -2489.5% | -1296.4% | ||
| Q1 24 | -3176.7% | -2793.9% |
| Q4 25 | — | — | ||
| Q3 25 | -4256.0% | -5899.2% | ||
| Q2 25 | -1643.8% | -9180.0% | ||
| Q1 25 | 13854.7% | -4886.1% | ||
| Q4 24 | -13556.1% | -1888.2% | ||
| Q3 24 | -1540.7% | -8166.8% | ||
| Q2 24 | 477.0% | -1259.5% | ||
| Q1 24 | -5023.5% | -2752.4% |
| Q4 25 | — | — | ||
| Q3 25 | $-3.04 | $-0.05 | ||
| Q2 25 | $-1.53 | $-0.06 | ||
| Q1 25 | $-2.11 | $-0.12 | ||
| Q4 24 | $-13.10 | $-0.15 | ||
| Q3 24 | $-3.07 | $-0.07 | ||
| Q2 24 | $0.81 | $-0.11 | ||
| Q1 24 | $-5.58 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | $74.9M |
| Total DebtLower is stronger | — | $19.2M |
| Stockholders' EquityBook value | $53.5M | $55.5M |
| Total Assets | $88.5M | $103.1M |
| Debt / EquityLower = less leverage | — | 0.35× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $77.8M | $74.9M | ||
| Q3 25 | $99.1M | $99.5M | ||
| Q2 25 | $122.9M | $91.4M | ||
| Q1 25 | $137.9M | $69.0M | ||
| Q4 24 | $56.9M | $74.7M | ||
| Q3 24 | $74.9M | $43.2M | ||
| Q2 24 | $94.5M | $56.6M | ||
| Q1 24 | $112.7M | $73.1M |
| Q4 25 | — | $19.2M | ||
| Q3 25 | — | $29.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $30.1M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $53.5M | $55.5M | ||
| Q3 25 | $71.8M | $90.7M | ||
| Q2 25 | $101.9M | $77.1M | ||
| Q1 25 | $116.4M | $53.2M | ||
| Q4 24 | $-29.0M | $48.8M | ||
| Q3 24 | $50.1M | $65.9M | ||
| Q2 24 | $67.2M | $78.7M | ||
| Q1 24 | $59.8M | $93.8M |
| Q4 25 | $88.5M | $103.1M | ||
| Q3 25 | $109.8M | $150.8M | ||
| Q2 25 | $134.7M | $140.6M | ||
| Q1 25 | $150.7M | $116.7M | ||
| Q4 24 | $70.1M | $121.2M | ||
| Q3 24 | $88.4M | $88.3M | ||
| Q2 24 | $108.8M | $103.4M | ||
| Q1 24 | $127.9M | $124.2M |
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.42× | ||
| Q1 25 | — | 0.57× | ||
| Q4 24 | — | 0.68× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-58.7M |
| Free Cash FlowOCF − Capex | — | $-59.4M |
| FCF MarginFCF / Revenue | — | -26636.3% |
| Capex IntensityCapex / Revenue | — | 304.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-103.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-82.5M | $-58.7M | ||
| Q3 25 | $-24.3M | $-16.5M | ||
| Q2 25 | $-15.5M | $-12.7M | ||
| Q1 25 | $-20.9M | $-14.1M | ||
| Q4 24 | $-18.4M | $-15.1M | ||
| Q3 24 | $-20.1M | $-14.1M | ||
| Q2 24 | $-19.5M | $-18.6M | ||
| Q1 24 | $-22.7M | $-20.8M |
| Q4 25 | — | $-59.4M | ||
| Q3 25 | — | $-16.6M | ||
| Q2 25 | — | $-12.9M | ||
| Q1 25 | — | $-14.2M | ||
| Q4 24 | — | $-15.2M | ||
| Q3 24 | — | $-14.1M | ||
| Q2 24 | — | $-18.8M | ||
| Q1 24 | — | $-20.9M |
| Q4 25 | — | -26636.3% | ||
| Q3 25 | — | -6894.6% | ||
| Q2 25 | — | -8346.5% | ||
| Q1 25 | — | -2410.4% | ||
| Q4 24 | — | -918.7% | ||
| Q3 24 | — | -7421.1% | ||
| Q2 24 | — | -989.5% | ||
| Q1 24 | — | -2183.4% |
| Q4 25 | — | 304.5% | ||
| Q3 25 | — | 53.1% | ||
| Q2 25 | — | 134.2% | ||
| Q1 25 | — | 16.8% | ||
| Q4 24 | — | 6.2% | ||
| Q3 24 | — | 4.7% | ||
| Q2 24 | — | 8.7% | ||
| Q1 24 | — | 11.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
